<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781001</url>
  </required_header>
  <id_info>
    <org_study_id>C06-SD-118</org_study_id>
    <nct_id>NCT00781001</nct_id>
  </id_info>
  <brief_title>Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy</brief_title>
  <official_title>Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Medicinal Cannabis Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Medicinal Cannabis Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vaporized cannabis is effective as an analgesic&#xD;
      for the treatment of painful diabetic neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuropathic pain is caused by an insult to the nervous system and accounts for 25-50% of all&#xD;
      pain clinic visits. Excluding low back pain, diabetic peripheral neuropathy is the most&#xD;
      common neuropathic pain syndrome with an estimated prevalence of 600,000 cases in the United&#xD;
      States. There are only 5 medications approved by the FDA for the treatment of neuropathic&#xD;
      pain with only 2 out of the 5 approved for the treatment of diabetic peripheral neuropathy.&#xD;
      Currently, there is a desperate need for more therapeutic agents for the treatment of&#xD;
      neuropathic pain. We propose to use painful diabetic peripheral neuropathy (DPN) patients to&#xD;
      study the efficacy of inhaled cannabis on neuropathic pain. We will enroll 20 subjects with&#xD;
      each subject acting as their own control; receiving both placebo and three doses of inhaled&#xD;
      aerosolized cannabis (low, medium, and high) in random order each separated by at least two&#xD;
      weeks. Subjects will be assessed for reduction in pain, changes in normal sensation, changes&#xD;
      in cognition, and effects of cannabis on experimentally induced pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous Pain Score</measure>
    <time_frame>Baseline, 5, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 mins post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute sensory threshold</measure>
    <time_frame>Baseline, 5, 30, 60, 90, 120, 150, 180, 210, 240 mins post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental pain score</measure>
    <time_frame>Baseline, 5, 30, 60, 90, 120, 150, 180, 210, 240 mins post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive testing</measure>
    <time_frame>Baseline, 60, 120, 240 mins post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective highness</measure>
    <time_frame>Baseline, 30, 60, 90, 120, 240 mins post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cannabis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active cannabis - 1% THC by weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active cannabis - 4% THC by weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active cannabis - 7% THC by weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  History of diabetes mellitus type 1 or type 2 who have stable glycemia and are&#xD;
             maintained by diet or a stable regimen of diabetic therapy for at least 12 weeks prior&#xD;
             to screening&#xD;
&#xD;
          -  Painful diabetic peripheral neuropathy for at least 6 months prior to screening with&#xD;
             symmetrical onset confirmed by neurological exam and a score of at least 3 on the&#xD;
             investigator section (physical exam) of the MNSI (Michigan Neuropathy Screening&#xD;
             Instrument) at screening.&#xD;
&#xD;
          -  Subject has a pain rating of at least 4 on the 11 point Numeric Pain Scale.&#xD;
&#xD;
          -  Patient is acceptable for enrollment as determined by the Investigator from the&#xD;
             medical history, physical exam finding, 12 lead ECG findings, and clinical laboratory&#xD;
             test results.&#xD;
&#xD;
          -  HbA1C&lt;11%.&#xD;
&#xD;
          -  For female patients, a negative urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active opportunistic infections or opportunistic malignancies requiring acute&#xD;
             treatment&#xD;
&#xD;
          -  Current or past cannabis abuse/dependence, or current other psychoactive drug use&#xD;
             disorder (e.g. opioids, methamphetamine, cocaine, alcohol)&#xD;
&#xD;
          -  Presence of significant cardiac or pulmonary disease (e.g., tuberculosis, asthma)&#xD;
&#xD;
          -  Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test&#xD;
             before any marijuana or placebo consumption condition.&#xD;
&#xD;
          -  Current serious mental illness--e.g. bipolar disorder, schizophrenia, or other&#xD;
             psychotic disorder&#xD;
&#xD;
          -  Other medical conditions that may lead to peripheral neuropathy&#xD;
&#xD;
          -  Females who are pregnant or planning pregnancy.&#xD;
&#xD;
          -  Females of child bearing potential not using a reliable means of birth control.&#xD;
&#xD;
          -  Lower extremity amputations other than toes. Patients must not have phantom pain from&#xD;
             amputated toes.&#xD;
&#xD;
          -  Other painful conditions or pain of vascular origin that may confound the assessment&#xD;
             of PDN.&#xD;
&#xD;
          -  Subjects with unstable blood glucose level (Fasting&lt; 70mg/dL or random blood glucose&#xD;
             level &gt; 250 mg/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S Wallace, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego, Hillcrest Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cmcr.ucsd.edu</url>
    <description>Center for Medicinal Cannabis Research</description>
  </link>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>diabetic neuropathy</keyword>
  <keyword>cannabis</keyword>
  <keyword>marijuana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

